In both SEER database and FUSCC dataset, HR+/HER2+ patients had the longest survival (38.00 vs 34.00 months), whereas triple negative breast cancer had the worst prognosis (9.00 vs 15.63 months). Here, ERBB2 is linked to triple-negative breast carcinoma.